Change of antioxidant protection indicators in patients with osteoarthritis in the course of the treatment with a combined chondroprotective drug

Abstract

Objective of the study. The study of changes in some parameters of the lipid peroxidation system - antioxidant protection, lipid spectrum in the course of the long-term therapy with the combined chondroprotective drug ARTRA in patients with knee osteoarthritis (OA) Methods. 24 patients with osteoarthritis of the knee joints with 1-3 X-ray stage of the disease (Kellgren and Lawrence, 1957) at the age of 41.8 ± 6.1 years were included in an open prospective study to evaluate the effects of CCD. The following indicators in serum and erythrocytes were determined: initial products of LPO (diene conjugates (DC), ketodienes and conjugated trienes (KD and CT)) in the heptane and isopropanol phase (the method of I.A. Volchegorsky, et al, 1989); intermediates (thiobarbituric acid test modified by L.I. Andreeva, et al, 1988); catalase activity (the method of M.A. Korolyuk et al., 1988); antioxidant activity of plasma (the method of M. Promyslov, 1990); peroxide erythrocyte resistance (G.A. Yarovaya, 1987). The quantitative determination of serum total cholesterol, low-density, very-low-density, high-density lipoprotein cholesterol, triglycerides was carried out using the ready-made CORMEY standardized sets (Germany). The patients’ condition and laboratory parameters were evaluated before the study, in 12 and 24 weeks after CCD was taken. Changes in the examined indicators were documented after a 24-week course. The inhibition of lipid peroxidation processes in the form of a decrease in the primary products and intermediates in the serum and erythrocytes was established. The study showed an increase in antioxidant protection (increased activity of blood serum catalase and erythrocytes and total antioxidant activity of blood serum). The patients’ tests showed a decrease in the concentration of total cholesterol and cholesterols of low-density lipoproteins. Conclusion. The study demonstrated the positive impact of ARTRA on the LPO-antioxidant protection system and the lipid spectrum in patients with OA following the 24-week administration.